CD8A and neoplasm: These results suggest that DTA-1 acts as a direct activator of CD8+ T cells, although we could not rule out the possibility that tumor-specific CD8+ T cell responses were increased by DTA-1 dose-dependent depletion of immune suppressive Treg cells.